** Shares of drugmaker Avadel Pharmaceuticals AVDL.O up 3% at $8.15 premarket
** Co posts Q4 net product revenue of $50.4 million on sales of its muscle weakness drug, Lumryz; above analysts' average estimate of $50.03 million, according to data compiled by LSEG
** Co reiterates 2025 forecast net product revenue of $240 million to $260 million, compared with estimates of $251.17 million
** AVDL has fallen 40% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.